Ute Graepler-Mainka
Overview
Explore the profile of Ute Graepler-Mainka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernhard W, Shunova A, Boriga J, Graepler-Mainka U, Hilberath J
Nutrients
. 2025 Mar;
17(5).
PMID: 40077735
Background: Exocrine pancreatic insufficiency in cystic fibrosis (CF) increases fecal choline losses, but the postnatal course of plasma choline and its metabolites in these patients is unknown. While choline homeostasis...
2.
Rumpf C, Janssen T, Hait R, Romme K, Decker C, Peters J, et al.
Am J Respir Crit Care Med
. 2025 Feb;
PMID: 39918841
Rationale: The mucoid phenotype of is caused by adaptation. Excessive biofilm formation associated with a protective effect for mucoid was observed in isolates from respiratory samples of people with cystic...
3.
Schwarz R, Schafer J, Utz P, Graepler-Mainka U, Dittmann H, Kraus M, et al.
Quant Imaging Med Surg
. 2025 Jan;
15(1):189-202.
PMID: 39838989
Background: Clinical severity and progression of lung disease in cystic fibrosis (CF) are significantly influenced by the degree of lung inflammation. Non-invasive quantitative diagnostic tools are desirable to differentiate structural...
4.
Mainz J, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, et al.
Front Pharmacol
. 2023 Nov;
14:1167407.
PMID: 38026920
Elexacaftor-tezacaftor-ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we...
5.
Bernhard W, Shunova A, Machann J, Grimmel M, Haack T, Utz P, et al.
Nutrition
. 2021 Jul;
89:111348.
PMID: 34217074
In cystic fibrosis (CF), 85% to 90% of patients develop exocrine pancreatic insufficiency. Despite enzyme substitution, low pancreatic phospholipase A2 (sPLaseA2-IB) activity causes fecal loss of bile phosphatidylcholine and choline...
6.
Kraus M, Teufel M, Esser M, Kiefer L, Fleischer S, Graepler-Mainka U, et al.
Rofo
. 2020 Feb;
192(6):567-575.
PMID: 32028538
Purpose: In cystic fibrosis (CF) the phenotypic expression of complaints varies widely. Genotypes with sufficient pancreatic function (PS) exhibit milder lung disease compared to CF patients with insufficient pancreatic function...
7.
Bernhard W, Lange R, Graepler-Mainka U, Engel C, Machann J, Hund V, et al.
Nutrients
. 2019 Mar;
11(3).
PMID: 30889905
Background: Choline is essential for the synthesis of liver phosphatidylcholine (PC), parenchymal maintenance, bile formation, and lipoprotein assembly to secrete triglycerides. In choline deficiency, the liver accretes choline/PC at the...
8.
Schaefer J, Hector A, Schmidt K, Teufel M, Fleischer S, Graepler-Mainka U, et al.
Eur Radiol
. 2017 Jul;
28(1):74-84.
PMID: 28664245
Objectives: To evaluate the applicability of a semiquantitative MRI scoring system (MR-CF-S) as a prognostic marker for clinical course of cystic fibrosis (CF) lung disease. Methods: This observational study of...
9.
Junge S, Gorlich D, den Reijer M, Wiedemann B, Tummler B, Ellemunter H, et al.
PLoS One
. 2016 Nov;
11(11):e0166220.
PMID: 27861524
Background: Staphylococcus aureus is an important pathogen in cystic fibrosis (CF). However, it is not clear which factors are associated with worse lung function in patients with persistent S. aureus...
10.
Riethmuller J, Herrmann G, Graepler-Mainka U, Hellwig D, Heuer H, Heyder S, et al.
Cell Physiol Biochem
. 2016 Sep;
39(3):1141-51.
PMID: 27576543
Background/aims: In cystic fibrosis (CF), chronic microbial lung infections are difficult to treat and cause morbidity and increased mortality. Methods: In a multicentre, open-label, exploratory, non-interventional study, inhaled tobramycin (300...